<DOC>
	<DOC>NCT03042130</DOC>
	<brief_summary>Patients with congestive heart failure, grade 3-4, in addition to the standard care, will be randomized 1:1. The study group will receive 2 doses of IV iron (Iron carboxymaltose). The control group will receive standard of care alone. The study will test for the effects of the additional IV iron on the symptoms, clinical picture and quality of life of the treated patients.</brief_summary>
	<brief_title>Treatment With IV Iron in Hospitalized Patients With Severe Heart Failure But Without Iron Deficiency</brief_title>
	<detailed_description>Patients with congestive heart failure, grade 3-4, in addition to the standard care, will be randomized 1:1. The study group will receive 2 doses of IV iron (Iron carboxymaltose). The control group will receive standard of care alone. The study will test for the effects of the additional IV iron on the symptoms, clinical picture and quality of life of the treated patients. The parameters that will be measured will include clinical, lab, echo, and quality of life questionnaires.</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Anemia, Iron-Deficiency</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Heart failure grade 34 Heart echo EF&lt; 40% (ejection fraction) Hb &gt; 10 mg/dL Iron&gt; 50 mic/dL Iron/ transferrin rate &gt; 20% Infection Acute ischemia Patients that didn't receive the standard of care during 3 days before investigational product administration Hemochromatosis Known allergy to one of the products of the investigational product. Macrocytic anemia Iron excess Pregnant women Mentally disabled patients which can't give their concent properly.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>